ascopubs.org

Expression of the receptor tyrosine kinase AXL and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma enrolled in the METEOR trial.

A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC). Anlotinib combined ...
The American Journal of Managed Care

Study Implicates AXL in Skin Cancer Development in CLL

The authors said their findings also suggest AXL inhibition might be an important therapeutic strategy. People with CLL have a higher risk of developing skin cancers, including SCC, explained ...
BioWorld

Chia Tai Tianqing Pharmaceutical divulges new AXL inhibitors

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has synthesized compounds acting as tyrosine-protein kinase receptor UFO (AXL) inhibitors reported to be useful for the treatment of cancer.
BioWorld

Hetero Labs describes new tyrosine kinase inhibitors

Hetero Labs Ltd. has identified angiopoietin-1 receptor (TEK; hTIE2), EGFR (HER1; erbB1), hepatocyte growth factor receptor (HGFR; MET), proto-oncogene tyrosine-protein kinase receptor ret (RET; ...